Compare Pfizer Inc (PFE) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs VNET Group Inc — how do they compare? Pfizer Inc trades at $27.95 (market cap $158.56B), while VNET Group Inc trades at $5.35 (market cap $1.47B). The key difference: Pfizer Inc is far larger — about 107.9× VNET Group Inc's market cap, and Pfizer Inc pays a 6.18% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and VNET Group Inc for 16 Days on average.
| PFE | VNET | |
|---|---|---|
Market Cap | $158.56B | $1.47B |
Volume | 44,138,282 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $29.02 | $14.03 |
52-Week Low | $23.67 | $5.13 |
Typical Hold Time | 158 Days | 16 Days |
Enterprise Value | $210.06B | $5.04B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
VNET trades at $5.39, near a 52-week low, with a bearish technical signal and negative earnings misses in recent quarters. The company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Positive cash flow from operations of $1.92 billion and a strategic investment closing in September 2026 provide some operational stability amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst consensus is moderately bullish with 62.5% buy ratings. Key risks include balance sheet pressures and competitive threats in the data center market, while potential upside hinges on execution of new capacity and AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
